Six infusions. No therapy. Now she's in my office.

She came to my office after doing a full series at a ketamine clinic. Six infusions. She sat in a recliner each time, tablet in hand. She could watch videos, play games, and listen to her own music. A nurse checked on her regularly. Nobody talked to her about what she might encounter or what to do with it afterward. She had depression and PTSD. She left confused and disappointed. She was hoping for something more than a dissociative hour with Netflix.

From fewer than 100 clinics in 2015, the U.S. ketamine market has grown to over 1,500 by 2024. This has been mostly without a federal regulatory framework. Now, oversight is defined by audits, enforcement actions, and charges rather than clear guidelines. Recent DEA and federal actions show the era of unregulated growth is ending.

For clinicians who carefully provide KAP, this moment can be particularly frustrating. Regulatory scrutiny focuses on documentation, individualized treatment plans, and physician supervision, not on whether anyone actually processed anything during those 45 minutes of dissociation.

The evidence is not controversial here: integration support isn't procedural decoration. Ketamine opens a window of neuroplasticity; what happens in that window matters. Preparation and integration shape how patients use the experience. Sending someone into a dissociative state with a Netflix queue and no framework is not a neutral act. It's a clinical failure dressed up as patient autonomy.

Ketamine mills scale by cutting the expensive parts. The therapeutic alliance. The careful screening. The real preparation and integration sessions. These take time, training, and genuine clinical skill. This means they compress margin. The clinic that gave my client a tablet had learned to extract the billable drug event from the labor of actually treating her. That is not a design flaw. It is the logic of commodified healthcare working exactly as intended.

For those of us who didn't cut those corners, this regulatory moment is worth naming. Your thorough intake, your preparation sessions, your actual integration work: these are clinically sound, ethically necessary, and now legally distinguishing. The paper trail of doing it right is the same paper trail that keeps you out of a DEA record-keeping investigation. That's a strange kind of vindication, but it's real.

What I'm curious about: when clients come to you post-ketamine mill, confused about why it didn't work, what do you tell them? How do you name what was missing?

— Peter

P.S. If you’re determined to elevate your KAP practice, enroll in my continuing education courses on clinical assessment, ethics, and ketamine-specific protocols. Take the next step toward providing the care your clients deserve. https://www.psychedelicaffirmingeducation.com/collections/continuing-education​